This site provides information on the EPIC study and details on case recruitment for veterinary professionals worldwide. Pimobendan is a prescription only medicine, licensed for the treatment of congestive heart failure due to mitral valve disease or dilated cardiomyopathy.

The EPIC Trial site is intended for veterinary professionals. By clicking 'Continue' you are affirming that you are a veterinary professional.



Evaluating Pimobendan in Cardiomegaly
Media & Journalists  •  Contact  •  Helpful Links  •  FAQs  •  Site Map
 

What is MMVD?


As the name suggests, myxomatous mitral valve disease, MMVD, affects the mitral valve, which is located on the left side of the heart between the atrium and the ventricle.  MMVD is a slowly progressive condition in which the mitral valve thickens. Normally, heart valves form a perfect seal when closed ensuring that blood flows in the right direction through the heart.  Therefore the function of the mitral valve is to channel blood from the left atrium into the left ventricle.  However, in MMVD the thickening of the mitral valve results in an imperfect seal and allows blood to “leak” backward into the atrium as the ventricle contracts.

How prevalent is MMVD?

MMVD affects about:

  • 10% of dogs between the ages of 5 and 8 years
  • 25% of dogs between the ages of 9 and 12 years
  • 35% of dogs more than 13 years

 

This form of heart disease usually occurs in small-to medium-size dogs. The most susceptible breeds are Cavalier King Charles Spaniels, Poodles, Schnauzers, Chihuahuas, and Fox Terriers. Also, male dogs are more commonly affected than females.

 

Investigator Sign in

Investigators, please sign in here.